STAT+: Pharmalittle: Pharma would lose loyal ally if Menendez leaves Senate; EMA to discuss anesthesia risk for weight-loss drugs
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Category: Pharma
STAT+: Just how much money do drugmakers gain from patent extensions?
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so…
STAT+: With Menendez indictment, pharmaceutical industry could lose a key ally
WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry…
Will a government shutdown stall Medicare drug price negotiations?
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
STAT+: Pharmalittle: FDA to furlough one-fifth of staff if government shuts down; FDA cites ‘grossly deficient’ data for ALS drug
Hello, everyone, and nice to see you again after we engaged in an extended respite….
STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, writing to…
STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny
Hello, everyone, and how are you this fine, sunny morning? We are doing just fine,…
STAT+: Approval setback for EpiPen alternative puts spotlight on common anti-competition tactic
Americans who suffer severe allergic reactions won’t have alternatives to autoinjectors like the Epipen for…
STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions
For the fourth time this year, Novartis has been reprimanded by a U.K. trade group…
STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
.jpg)
STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro
As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding…
STAT+: How a cash-prize system that phases out patents may lower drug prices
Two months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he…
STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism
WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of…
STAT+: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost
Following a high-profile pressure campaign, the company that makes a crucial tuberculosis test has agreed…
STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: South Africa investigates Johnson & Johnson over ‘excessive pricing’ for its TB drug
South African authorities are investigating Johnson & Johnson and its Janssen subsidiary over “excessive pricing”…
STAT+: Chamber of Commerce, government clash at first court hearing on Medicare drug prices
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday…
STAT+: Pharmalittle: House panel inches into fixing drug shortages; pharma could face legal action over improper patent listings
And so, another working week will soon draw to a close. Not a moment too…
Johnson & Johnson is getting rid of its script logo after more than 130 years
Johnson & Johnson is signing off on a new logo. The health care giant said…
STAT+: House subcommittee forays into fixing drug shortages
WASHINGTON — A House subcommittee took a first step today toward legislation to fix drug…
STAT+: FTC warns drugmakers they can face legal action over improper patent filings
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly…
.jpg)
STAT+: Medicare is urged to monitor how rebates affect Part D drug spending, but agency demurs
The U.S. government should monitor the effect that rebates have on Medicare Part D plans…
STAT+: Pharmalittle: White House imposes price limits for Regeneron Covid drug; lawmakers push federal agencies to prevent patent abuses
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Civica Rx considers moving into chemo drugs as shortages worsen
WASHINGTON — A nonprofit formed by hospitals to deal with drug shortages is considering a…
Novelist John Green launches attack on Cepheid over the price of its TB test
John Green, a novelist and high-profile YouTuber, is once again leveraging his star power in…
STAT+: Lawmakers introduce bill to require drugmakers to provide key info to both FDA and U.S. Patent Office
Amid concerns over monopolies held by drugmakers, a bipartisan group of lawmakers introduced a bill…
STAT+: In new Regeneron deal for Covid drug, Biden administration imposes price limits for first time
WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and…
STAT+: Pharmalittle: FDA panel says popular decongestant doesn’t work; U.S. warns companies over illegally marketed eye products
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Opinion: STAT+: The IRA needs changes to better support patients with rare diseases
This time last year, members of Congress were working around the clock to draft and…
STAT+: White House touts efforts to stem cancer drug shortages
WASHINGTON — The White House says it’s working to end shortages of three key generic…
STAT+: Pharmalittle: Is Pascal Soriot leaving AstraZeneca? PBMs try to counter congressional crackdown
Hello, everyone, and nice to see you again after our extended break. A little time…
STAT+: Pharmalittle: Biden’s NIH nominee will get a hearing; top Democrat backs bill to ban PBM spread pricing
Good morning, Jason Mast here filling in for Ed. Today, I’m drinking a cup of…
STAT+: Crinetics acromegaly drug succeeds in late-stage trial but would face stiff competition if approved
SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a…
STAT+: Pharmalittle: Novartis R&D hub’s name change reflects strategy shift; Lilly’s Mounjaro backed by U.K. watchdog
Good morning, Pharmalittle family! Adam Feuerstein here, filling in for Ed. My morning coffee was…
STAT+: Why Novartis is changing the name of its research labs
Swiss drugmaker Novartis’ research and development hub has a new name — and a new…
STAT+: Pharmalittle: South Africa ‘bullied’ into one-sided Covid vaccine deals; Astellas drops Medicare price-negotiation suit
Good morning, everyone. Jason Mast here filling in for Ed. I learned today from TikTok…
STAT+: Why the drug industry’s opaque warnings on price negotiations fall short
Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry…
STAT+: AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing bill’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a…
STAT+: South Africa was forced into ‘one-sided’ deals with Covid-19 vaccine suppliers, contracts reveal
South Africa was “bullied” into signing one-sided contracts with Covid-19 vaccine suppliers that forced the…
STAT+: Pharmalittle: Novartis is losing its chief commercial officer; vaccine experts urge more inclusivity in clinical trials
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Pharmalittle: Novartis is latest drugmaker to sue over Medicare negotiations; Illumina names a new CEO
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: FTC settles with Amgen over $28 billion deal for Horizon
After months of legal sparring, Amgen and Horizon Therapeutics settled a lawsuit with the U.S….
STAT+: Pharmalittle: How 98 days may cost J&J big bucks; Walgreens CEO departs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: U.S. pharma layoffs continue to climb; senators push insulin makers for details of low-cost programs
Top of the morning to you, and a fine one it is. Blue skies and…
STAT+: J&J cuts the price of its life-saving TB pill by more than half for many low and middle-income countries
Amid controversy over access to a life-saving tuberculosis pill, a new contracting effort is expected…
STAT+: Pharmalittle: Winners and losers from Medicare drug-negotiation list; Novo strikes deal to keep lead in weight-loss drugs
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: U.S. selects first 10 drugs for Medicare price negotiations; Pfizer may soon restart tornado-hit plant
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: FDA delays enforcement of a pharmaceutical supply chain law to stop counterfeit drugs
In response to growing complaints, the U.S. Food and Drug Administration has postponed its plans…